Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
BCPC · NASDAQ · Specialty Chemicals
Balchem Corporation (BCPC) · oqro.io/stocks/BCPC · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Baskets of the companies that insiders, members of Congress or funds recently reported buying, each held under a written rule.
No open-market purchase by an insider of Balchem Corporation was filed in the last 90 days. The latest on record was on Aug 5, 2019.
Since 2006, Balchem Corporation insiders reported 9 open-market purchases and 508 sales on Forms 4 and 5, with purchases in 5 different years, most recently 2019.
No open-market sale by an insider of Balchem Corporation (BCPC) was filed with the SEC in the last 90 days.
Yes. Members of Congress disclosed 2 trades in Balchem Corporation (BCPC) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Rep. Gilbert Ray Cisneros Jr. (CA31).
Balchem Corporation's next results are expected on Feb 18, 2027, before the market opens. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$163.54−2.00 (−1.21%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
+7.1% (+$10.82) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $152.72 on Nov 20, 2025 to $163.54 on Nov 20, 2026 (+7.1%). Disclosed in this range: 4 insider trades, 0 pre-arranged insider sales, 2 Congress trades, and 15 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Specialty Chemicals company based in Montvale, New Jersey.
Last 12 months
+7.1%
Market value
$5.26B
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 504K shares sold short (1.6% of shares outstanding), −2.6% vs the previous count, 1.5 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Balchem Corporation: 1 fund opened or increased a position in the latest available 13F filings and 1 member of Congress disclosed purchases. 2 of 3 tracked groups show buying activity. Based on public disclosures; it does not say why, or what happens next. Our test of this pattern
Revenue, fiscal 2025
$1.04B
+8.8% vs the year before
Net income, fiscal 2025
$155M
As reported in the annual filing
Shares outstanding
31.8M
As of Oct 15, 2026
In fiscal 2025 the company spent $108M buying back its own shares and $28.3M on dividends. Cash actually paid, from its cash-flow statement.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Congress
Traded Sep 17 · disclosed 25 days later
Since the trade −1.3% · S&P 500 −9.5% · to Nov 20
Bought 10% below the 52-week high, RSI 39
Congress
Traded Jul 10 · disclosed 56 days laterLate
Since the trade +0.9% · S&P 500 −8.6% · to Nov 20
Bought 12% below the 52-week high, RSI 40, 18 points behind the S&P 500 over 3 months
Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
9 tracked managers disclosed the same change for Q2 2026. From a 13F filed Jul 29, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
No Schedule 13D or 13G filing on BCPC over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Insiders of Balchem Corporation reported 9 open-market purchases and 508 sales since 2006; purchases in 5 different years, most recently 2019.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $2.34M5×5 trades |
| 2024 | — | $20.8M26×26 trades |
| 2023 | — | $1.18M3×3 trades |
| 2022 | — | $1.09M5×5 trades |
| 2021 | — | $3.03M2×2 trades |
| 2020 | — | $309K1×1 trade |
| 2019 | $254K1×1 trade | $1.15M2×2 trades |
| 2018 | $58K1×1 trade | — |
| 2017 | — | $5.67M5×5 trades |
| 2016 | — | $12.9M26×26 trades |
| 2015 | — | $20.6M36×36 trades |
| 2014 | $958K2×2 trades | $23.6M33×33 trades |
| 2013 | — | $28.1M54×54 trades |
| 2012 | $195K2×2 trades | $4.86M10×10 trades |
| 2011 | — | $5.33M18×18 trades |
| 2010 | — | $7.94M26×26 trades |
| 2009 | — | $7.01M20×20 trades |
| 2008 | $238K3×3 trades | $1.66M2×2 trades |
| 2007 | — | $153M17×17 trades |
| 2006 | — | $3.88M217×217 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Against the S&P 500 over the year
Since Nov 18, 2025, BCPC is up 7.5% and the index fund is up 8.5%: about the same. Traders call a stock that beats the index over a period a relative-strength leader.
How much BCPC moves
Beta 0.2 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 250 trading days (1 = in step with it).
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Revenue
$291M
+8.6% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $66.3M, at Sep 30, 2026
Net income, last 12 months
$171M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 23, 2026.
Revenue and earnings history, 17 fiscal yearsEarnings dates and the stock's moves
Who holds it
Things to keep in mind
Records
3 certified in FY2026 Q3, vs 0 a year earlier. 3 positions in total, median offered wage $100K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Latest annual report filed Feb 20, 2026, compared with the one filed Feb 21, 2025. Read the filing
All 26 risk factor headings match the year before, give or take wording.
In the normal course of business, we are involved in a variety of lawsuits, claims and legal proceedings, from time to time, including commercial and contract disputes, labor and employment matters, product liability claims, environmental liabilities, trade regulation matters, intellectual property disputes and tax-related matters. Further, in connection with normal operations at our plant facilities, our manufacturing sites may, from time to time, be subject to inspections or inquiries by the EPA and other agencies.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 20, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Last results
Oct 23, 2026
Within the 30 days after it, until Nov 22, 2026
Next results, expected
Feb 18, 2027
before the market opens; the date can move until the company confirms it
Purchases after results
Not enough history
From Balchem Corporation's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Balchem Corporation's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Oct 23, 2026. Quarterly reports are not audited. Read the filing
+8.1% on the same quarter a year earlier ($174M). Operating income $45.6M, a 24% margin
+12% on the same quarter a year earlier ($56.4M). Operating income $6.79M, a 11% margin
+4.5% on the same quarter a year earlier ($35.7M). Operating income $12.3M, a 33% margin
The segments reach the total once $2.15M of items outside them is counted: corporate items, and the removal of sales between segments so they are not counted twice, as the company reports them.
+8.7% on the same quarter a year earlier ($267M)
−16% on the same quarter a year earlier ($480K)
+7.5% on the same quarter a year earlier ($198M)
+12% on the same quarter a year earlier ($69.5M)
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 20, 2026. Read the filing
+9.9% on the year before ($600M). Operating income $154M, a 23% margin
+7.5% on the year before ($215M). Operating income $18.7M, a 8% margin
+6.2% on the year before ($133M). Operating income $42.9M, a 30% margin
The segments reach the total once $5.95M of items outside them is counted: corporate items, and the removal of sales between segments so they are not counted twice, as the company reports them.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 3,000 words.
We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, plant nutrition, sterilization, fumigation, and industrial markets. Our three reportable segments are strategic businesses that offer products and services to different markets: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products, as more fully described in Note 10, Segment Information, of the consolidated financial statements. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".
Source: SEC EDGAR, Form 10-K filed Feb 20, 2026 and Form 10-Q filed Oct 23, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
+8.8% on the year before ($952M)
+8.8% on the year before ($1.74M)
+5.0% on the year before ($723M)
+21% on the year before ($230M)
And 10 more headings in the filing.
Off-exchange trading: 51.1% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (17.6% on ATS, 33.5% with other brokers), above its 26-week average of 43.7%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: SIGMA X2 (15.0%), UBS ATS (13.9%), INTELLIGENT CROSS LLC (11.4%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.